Takeda Pharmaceutical Company Limited (TSE:4502) exercised an option to acquire Adaptate Biotherapeutics Ltd from Abingworth LLP on January 10, 2022. The acquisition is subject to completion of review under applicable antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S. The acquisitions of Adaptate is expected to be finalised in first quarter of Takeda's fiscal year 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,125 JPY | -0.43% | +0.88% | +1.75% |
04-30 | Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion | RE |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.75% | 42.33B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited exercised an option to acquire Adaptate Biotherapeutics Ltd from Abingworth LLP.